VIDEO: Assessing best duration of azacitidine plus venetoclax in older patients with AML
Click Here to Manage Email Alerts
Healio spoke with Naval Daver, MD, about a debate on the best duration of venetoclax in combination with azacitidine among older patients with acute myeloid leukemia from Society of Hematologic Oncology Annual Meeting.
Daver explained that in the debate, Keith Pratz, MD, director of the leukemia program at Penn Medicine, discussed the current approach of 28 days continuous treatment and Stéphane De Botton, MD, PhD, of the Institut Gustave Roussy in Villejuif, France, discussed a shorter treatment duration of 14 or 7 days.
“This is quite important because we’re starting to realize that with longer durations of venetoclax [Venclexta; AbbVie, Genentech], we may be having significant myelosuppression and toxicity, and maybe we can get the same outcome with a shorter duration,” Daver, professor and director of the Leukemia Research Alliance Program in the department of leukemia at The University of Texas MD Anderson Cancer Center, said. “So, this debate with quite interesting, with a lot of new data.”
References:
- De Botton, S. Debate: Dose reductions in azacytidine plus venetoclax are not detrimental. Presented at: Society of Hematologic Oncology Annual Meeting; Sept. 4-7, 2024; Houston.
- Pratz K. Debate: Azacytidine plus venetoclax should be prescribed as listed on the label. Presented at: Society of Hematologic Oncology Annual Meeting; Sept. 4-7, 2024; Houston.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts